目的 探讨氨基葡萄糖联合布洛芬治疗髋关节骨关节炎的临床疗效。 方法 2011年9月－2012年1月采用前瞻性随机对照临床试验，将198例轻、中度髋关节骨关节炎患者随机分入试验组及对照组。试验组采用氨基葡萄糖（750 mg， 2次/d口服，疗程1个月）联合布洛芬（0.3 g，2次/d口服，疗程2周），对照组则单用布洛芬（0.3 g，2次/d口服，疗程2周）；分别于服药后0、2、4、8及12周时采用加拿大西安大略和麦克玛斯特大学骨关节炎指数（WOMAC）进行疗效评价。并对恶心、呕吐、皮疹等药物不良反应进行观察。 结果 试验组与对照组WOMAC各项评分从第2周开始较0周明显下降，而两组患者间在0周及2周时WOMAC评分无统计学差异：0周总评分（45.3、45.0分，P=0.225），2周总评分（37.3、37.6分，P=0.329）。但对照组WOMAC各项评分从第4周开始逐渐呈现上升趋势，而试验组到第12周仍呈现持续性下降趋势。总不良反应发生率为7.0%，其中试验组总不良反应发生率为9.5%，但不良反应轻微，未予特殊处理而自行消失。 结论 氨基葡萄糖联合布洛芬可有效缓解早、中期髋关节骨关节炎各项临床症状，疗效确切，不良反应较少，且停药后仍持续表现出治疗效果。而单用布洛芬可短期缓解骨关节炎症，但停药后症状逐渐复现。
In recent years, reports of domestic robot-assisted total knee arthroplasty have gradually increased. In response to problems that may arise during the perioperative period, West China Hospital of Sichuan University has adopted measures such as the establishment of multidisciplinary team, adequate preoperative evaluation, precise intraoperative operations, and whole process optimization management (incision management, pain management, functional exercise and follow-up management). Combined with the actual clinical situation, a domestic robot-assisted total knee arthroplasty management program during the perioperative period was explored and formulated to promote the recovery of patients. This article introduces the above-mentioned program, and aims to provide a reference for the management optimization of domestic robot-assisted total knee arthroplasty during the perioperative period.